血管生成素2(ANGPT2)檢測試劑盒(化學(xué)發(fā)光免疫分析法)
CLIA Kit for Angiopoietin 2 (ANGPT2)
ANG2; AGPT2
- 編號SCA009Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長2h, 40min
- 檢測范圍6.9-5,000pg/mL
- 靈敏度最小可檢測劑量小于等于2.9pg/mL.
- 樣本類型Serum, plasma, tissue homogenates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 3528 ¥ 5040 ¥ 22680 ¥ 42840 ¥ 352800
- 欲了解實(shí)際交易價(jià)格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測血管生成素2(ANGPT2)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的血管生成素2(ANGPT2)（加標(biāo)樣品），重復(fù)測定并計(jì)算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 98-105 | 102 |
| EDTA plasma(n=5) | 90-97 | 94 |
| heparin plasma(n=5) | 93-102 | 97 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定，每個(gè)樣本使用同一試劑盒重復(fù)測定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的血管生成素2(ANGPT2)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中血管生成素2(ANGPT2)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 81-91% | 87-103% | 96-103% | 96-103% |
| EDTA plasma(n=5) | 85-95% | 93-101% | 87-96% | 80-98% |
| heparin plasma(n=5) | 86-94% | 85-102% | 84-95% | 99-105% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測溶液A100μL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加底物100µL，37°C孵育10分鐘；
8. 讀數(shù)。
實(shí)驗(yàn)原理
將血管生成素2(ANGPT2)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的血管生成素2(ANGPT2)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的血管生成素2(ANGPT2)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入底物。加入底物后會(huì)產(chǎn)生輝光型光信號。發(fā)射光強(qiáng)度和樣品中的血管生成素2(ANGPT2)呈正相關(guān)。用化學(xué)發(fā)光儀測定相對光單位（RLU），計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA009Hu03 | 血管生成素2(ANGPT2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA009Hu01 | 血管生成素2(ANGPT2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA009Hu02 | 血管生成素2(ANGPT2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA009Hu01 | 血管生成素2(ANGPT2)活性蛋白 | Cell?culture;?Activity?Assays. |
| PAA009Hu02 | 血管生成素2(ANGPT2)多克隆抗體 | WB |
| PAA009Hu01 | 血管生成素2(ANGPT2)多克隆抗體 | WB,IHC |
| LAA009Hu71 | 血管生成素2(ANGPT2)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| MAA009Hu22 | 血管生成素2(ANGPT2)單克隆抗體 | WB; IHC; ICC; IP. |
| RAA009Hu21 | 血管生成素2(ANGPT2)重組抗體 | WB; IF; ICC; IHC; IP; FCM. |
| SEA009Hu | 血管生成素2(ANGPT2)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCA009Hu | 血管生成素2(ANGPT2)檢測試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMA009Hu | 血管生成素2(ANGPT2)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Microvascular Research | Mutant hypoxia inducible factor-1α improves angiogenesis and tissue perfusion in ischemic rabbit skeletal muscle [PubMed: 20937289] |
| Theriogenology | Evaluation of Changes in Doppler Ultrasonography Indices and Levels of Maternal Serum Angiogenic Factors throughout Pregnancy in Ewes [Science: Article] |
| Pediatr Infect Dis J | Important of Angiopoietic System in Evaluation of Endothelial Damage in Children with Crimean–Congo Hemorrhagic Fever [PubMed: 25831422] |
| Oncotarget | Long noncoding RNA hotair mediated angiogenesis in nasopharyngeal carcinoma by direct and indirect signaling pathways [Pubmed:26717040] |
| Experimental?Animals | Ginsenoside?Rb1?improves?cardiac?function?and?remodeling?in?heart?failure. [pubmed:28367863] |
| Sci Rep.? | Flunarizine suppresses endothelial Angiopoietin-2 in a calcium - dependent fashion in sepsis. [pubmed:28276491] |
| PeerJ? | The ratio of serum Angiopoietin-1 to Angiopoietin-2 in patients with cervical cancer is a valuable diagnostic and prognostic biomarker [pubmed:28584715] |
| Cellular Physiology and Biochemistry | Angiotensin-(1-7) in Paraventricular Nucleus Contributes to the Enhanced Cardiac Sympathetic Afferent Reflex and Sympathetic Activity in Chronic Heart Failure Rats [pubmed:28848201] |
| Tumor Biology | Cervical cancer cell–derived angiopoietins promote tumor progression [pubmed:28720059] |
| Anesthesiology | Vasculotide, an angiopoietin-1 mimetic, restores microcirculatory perfusion and microvascular leakage and decreases fluid resuscitation requirements in?… [Pubmed:28968277] |
| British Journal of Anaesthesia | Vasculotide, an angiopoietin-1 mimetic, reduces pulmonary vascular leakage and preserves microcirculatory perfusion during cardiopulmonary bypass in rats [10.1016:j.bja.2018.05.049] |
| Anticancer?Research | Oligodendrocytes Up-regulate the Invasive Activity of Glioblastoma Cells via the Angiopoietin-2 Signaling Pathway [Pubmed: 30711932] |
| Comparative Medicine | Characterization of a Porcine Model for Von Willebrand Disease Type 1 and 3 Regarding Expression of Angiogenic Mediators in the Nonpregnant Female?… [Pubmed: 31526432] |
| BMC Endocrine Disorders | The role of the adipocytokines vaspin and visfatin in vascular endothelial function and insulin resistance in obese children [Pubmed: 31771561] |
| Biology of Reproduction | Expression of angiogenic factors in the uteroplacental unit is altered at time of placentation in a porcine model of von Willebrand disease type 1 [Pubmed: 31806575] |
| Scientific Reports | Association between Upper-airway Surgery and Ameliorative Risk Markers of endothelial function in obstructive Sleep Apnea [Pubmed: 31882827] |
| MEDIATORS OF INFLAMMATION | Mica Can Alleviate TNBS-Induced Colitis in Mice by Reducing Angiotensin II and IL-17A and Increasing Angiotensin-Converting Enzyme 2, Angiotensin 1-7?… [Pubmed: 33100902] |
| Scientific Reports | Integrated metabolomics and gut microbiome to the effects and mechanisms of naoxintong capsule on type 2 diabetes in rats [Pubmed: 32616735] |
| Intensive Care Med Exp | The effect of targeting Tie2 on hemorrhagic shock-induced renal perfusion disturbances in rats [33997943] |
| Gynecol Endocrinol | Potential of thrombospondin-1 in treatment of polycystic ovary syndrome rat model: a preliminary study [34282706] |
| Clinical and Experimental Immunology | Clinical significance of differential serum-signatures for early prediction of severe dengue among Eastern Indian patients [Pubmed:35348620] |
